**Question:** True statement about phase 2 clinical trial is:

A. Participants are not أعمىed or placebo controlled
B. The trial is conducted to determine the optimal dose and side effects
C. The trial is conducted to determine effectiveness and safety
D. The trial is conducted to determine the optimal dose and safety

**Core Concept:**
Phase 2 clinical trials are a crucial part of drug development, following the safety evaluation in phase 1. These trials aim to determine the optimal dose, side effects, effectiveness, and further evaluate the safety of a drug or treatment in a larger group of patients with the disease or condition of interest.

**Why the Correct Answer is Right:**
Phase 2 trials focus on evaluating the optimal dose and understanding the drug's safety profile. In this case, option D is correct as it highlights the main goals of phase 2 trials: determining the optimal dose and safety. Participants are not necessarily blinded or placebo-controlled in phase 2 trials, but the focus is on these aspects rather than therapeutic efficacy.

**Why Each Wrong Option is Incorrect:**
A) Option A is incorrect as phase 2 trials are not exclusively about not being blinded or placebo-controlled. Although they might not employ these methodologies as strictly, the primary goals are still determining the optimal dose and safety.
B) Option B is partially correct as phase 2 trials do evaluate side effects, but they primarily assess the drug's effectiveness and safety. Blinding and placebo control are not the primary focus of phase 2 trials.

**Why Option C is Incorrect:**
Option C mentions determining effectiveness, which is not the main focus of phase 2 trials. Their main focus is on determining the optimal dose and safety, not assessing the overall effectiveness of the drug or treatment.

**Clinical Pearl:**
Phase 2 clinical trials serve as a bridge between phase 1 and phase 3 trials, where efficacy and effectiveness are more rigorously evaluated. These trials help identify optimal dosing, side effects, and preliminary efficacy data, which can guide the approach for phase 3 trials. While these trials are not blinded or placebo-controlled, they focus on determining the drug's safety, optimal dose, and preliminary efficacy.